Dual Checkpoint Blockade Usurps PD-1 Monotherapy as Gold Standard in Unresectable Melanoma

Source: OncLive , August 2024

Updated findings from the phase 2/3 RELATIVITY-047 trial (NCT03470922) showing sustained responses and favorable survival outcomes with nivolumab (Opdivo) plus relatlimab-rmbw (Opdualag) in previously untreated patients with metastatic or unresectable melanoma signal the diminishing role for anti–PD-1 monotherapy in the frontline setting, according to Ankit Mangla, MD.

Three-year follow-up data from RELATIVITY-047 presented at the 2024 ASCO Annual Meeting demonstrated a progression-free survival (PFS) advantage with nivolumab plus relatlimab (n = 355) vs nivolumab alone (n = 359) in this patient population (HR, 0.79; 95% CI, 0.66-0.95). Notably, a trend in favor of the combination was seen for overall survival (OS; HR, 0.80; 95% CI, 0.66-0.99), with 3-year OS rates of 55% (95% CI, 49.2%-59.6%) vs 48% (95% CI, 42.7%-53.1%), respectively.

Improvements in melanoma-specific survival (MSS) observed with the combination over nivolumab alone (HR, 0.75; 95% CI, 0.60-0.94) were also maintained; 3-year MSS rates were 63% (95% CI, 57.2%-67.7%) vs 54% (95% CI, 48.4%-59.2%), respectively. MSS, central nervous system (CNS) metastasis-free survival in specified populations, and efficacy on subsequent systemic therapy represented exploratory analyses presented from the trial. Additionally, efficacy results were consistent across most patient subgroups.
READ THE ORIGINAL FULL ARTICLE